NL-OMON39922
Completed
Not Applicable
Markers to Determine Arrhythmia Vulnerability in End Stage Heart Failure. - Arrhythmia vulnerability in heart failure, AVES-HF
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- arrhythmia
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients will be included if they are over 18 years and under 80 years and able to give informed consent.
- •Patients with end stage heart failure undergoing LVAD implantation.
Exclusion Criteria
- •Under 18 and over 80 years
- •The inclusion criteria includes only the study population.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Identifikation of arrhythmogenic Substrate using echocardiography and MRII48I47Atrial fibrillation and flutterParoxysmal tachycardiaDRKS00017088Charité Campus Charité Mitte120
Completed
Not Applicable
Cardiomyopathy Arrhythmia Risk EvaluationCardiomyopathyNCT02560844University Health Network, Toronto164
Completed
Not Applicable
Arrhythmia Risk Stratification in a Clinical Patient Cohort and Correlation with Genotype and Environmental Modulatorsarrhythmia risk stratification1000752110007510NL-OMON37942Academisch Medisch Centrum100
Completed
Not Applicable
ECG markers for mortality prediction in COVID-19Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2022/04/041892Yenepoya University150
Active, not recruiting
Not Applicable
Discovery of New Biomarkers of Cardiac Susceptibility in adults with Fabry Disease that may be used to develop Targeted Fabry-Specific Therapy DeliveryFabry DiseaseHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersMetabolic and Endocrine - Metabolic disordersACTRN12622000418774The University of Sydney50